MP06-13 inhibition of human prostate stromal cell growth and modulation of cytoskeletal organization by lenalidomide: a NEW treatment option in male luts?
Abstract
INTRODUCTION AND OBJECTIVES: Medical treatment in benign prostatic hyperplasia (BPH) includes reduction of prostate size to prevent disease progression, complications, and surgery, and also reduction of prostate smooth muscle tone for rapid relieve of lower urinary tract symptoms (LUTS). Combination therapies are still required to target both at once. However, current medications are insufficient, causing high rates of patient non-compliance due to an unfavourable balance between side effects and efficacy, with discontinuation rates peaking up to 90% for combination therapies. Here, we investigated the effect of lenalidomide on cellular functions including cytoskeletal organization and growth of prostate stromal cells. METHODS: Experiments were carried out in an immortalized line of cultured human prostate stromal cells (WPMY-1). Cytoskeletal organization was visualized by phalloidin staining, while cell growth was assessed using an EdU and Colony formation assay. Cytotoxicity was addressed using CCK8. RESULTS: Lenalidomide significantly reduced the proliferation of WPMY-1 cells. This decline was concentration-dependent, with a significantly lower proliferation rate after 72 hours of incubation. Thus, proliferation was reduced after 72 h from 64% for control to 37% and 34% for 100 and 200 µM, (p<0.01 for lenalidomide vs. control, fig. 1 A and B). Also, colony formation was reduced after 168 h to 65% and 53% for 100 and 200 µM, respectively (p<0.01 for lenalidomide vs.…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.